# Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

> **NCT01777776** · PHASE1,PHASE2 · TERMINATED · sponsor: **Array BioPharma** · enrollment: 28 (actual)

## Conditions studied

- Locally Advanced Metastatic BRAF Mutant Melanoma

## Interventions

- **DRUG:** LEE011
- **DRUG:** LGX818

## Key facts

- **NCT ID:** NCT01777776
- **Lead sponsor:** Array BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Study was withdrawn due to scientific and business considerations.
- **Last updated:** 2016-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01777776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01777776, "Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01777776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*